tradingkey.logo

Evolus Inc

EOLS
查看詳細走勢圖
6.900USD
+0.050+0.73%
收盤 12/26, 16:00美東報價延遲15分鐘
446.89M總市值
虧損本益比TTM

Evolus Inc

6.900
+0.050+0.73%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.73%

5天

-2.40%

1月

-1.99%

6月

-24.51%

今年開始到現在

-37.50%

1年

-37.78%

查看詳細走勢圖

TradingKey Evolus Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

Evolus Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名52/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價18.50。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Evolus Inc評分

相關信息

行業排名
52 / 158
全市場排名
130 / 4563
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 7 分析師
買入
評級
18.500
目標均價
+165.42%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Evolus Inc亮點

亮點風險
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
業績高增長
公司營業收入穩步增長,連續3年增長79.17%
估值高估
公司最新PE估值-7.59,處於3年歷史高位
PRFDX持倉
明星投資者PRFDX持倉,最新持倉20.74K股
活躍度增加
近期活躍度增加,過去20天平均換手率1.68

Evolus Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Evolus Inc簡介

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
公司代碼EOLS
公司Evolus Inc
CEOMoatazedi (David)
網址https://www.evolus.com/

常見問題

Evolus Inc(EOLS)的當前股價是多少?

Evolus Inc(EOLS)的當前股價是 6.900。

Evolus Inc 的股票代碼是什麼?

Evolus Inc的股票代碼是EOLS。

Evolus Inc股票的52週最高點是多少?

Evolus Inc股票的52週最高點是17.120。

Evolus Inc股票的52週最低點是多少?

Evolus Inc股票的52週最低點是5.710。

Evolus Inc的市值是多少?

Evolus Inc的市值是446.89M。

Evolus Inc的淨利潤是多少?

Evolus Inc的淨利潤為-50.42M。

現在Evolus Inc(EOLS)的股票是買入、持有還是賣出?

根據分析師評級,Evolus Inc(EOLS)的總體評級為買入,目標價格為18.500。

Evolus Inc(EOLS)股票的每股收益(EPS TTM)是多少

Evolus Inc(EOLS)股票的每股收益(EPS TTM)是-0.909。
KeyAI